tbuckley/cabot-search huggingface dataset:
Six‐Transmembrane Epithelial Antigen of the Prostate 3 Deficiency in Hepatocytes Protects the Liver Against Ischemia‐Reperfusion Injury by Suppressing Transforming Growth Factor‐β‐Activated Kinase 1
Authors: Wen‐Zhi Guo, Hong‐Bo Fang, Sheng‐Li Cao, San‐Yang Chen, Jie Li, Ji‐Hua Shi, Hong‐Wei Tang, Yi Zhang, Pei‐Hao Wen, Jia‐Kai Zhang, Zhi‐Hui Wang, Xiao‐Yi Shi, Chun Pang, Han Yang, Bo‐Wen Hu, Shui‐Jun Zhang
Journal: Hepatology (2019)

Background and Aims Hepatic ischemia‐reperfusion (I/R) injury remains a major challenge affecting the morbidity and mortality of liver transplantation. Effective strategies to improve liver function after hepatic I/R injury are limited. Six‐transmembrane epithelial antigen of the prostate 3 (Steap3), a key regulator of iron uptake, was reported to be involved in immunity and apoptotic processes in various cell types. However, the role of Steap3 in hepatic I/R‐induced liver damage remains largely unclear. Approach and Results In the present study, we found that Steap3 expression was significantly up‐regulated in liver tissue from mice subjected to hepatic I/R surgery and primary hepatocytes challenged with hypoxia/reoxygenation insult. Subsequently, global Steap3 knockout ( Steap3‐ KO) mice, hepatocyte‐specific Steap3 transgenic ( Steap3‐ HTG) mice, and their corresponding controls were subjected to partial hepatic warm I/R injury. Hepatic histology, the inflammatory response, and apoptosis were monitored to assess liver damage. The molecular mechanisms of Steap3 function were explored in vivo and in vitro . The results demonstrated that, compared with control mice, Steap3‐ KO mice exhibited alleviated liver damage after hepatic I/R injury, as shown by smaller necrotic areas, lower serum transaminase levels, decreased apoptosis rates, and reduced inflammatory cell infiltration, whereas Steap3‐ HTG mice had the opposite phenotype. Further molecular experiments showed that Steap3 deficiency could inhibit transforming growth factor‐β–activated kinase 1 (TAK1) activation and downstream c‐Jun N‐terminal kinase (JNK) and p38 signaling during hepatic I/R injury. Conclusions Steap3 is a mediator of hepatic I/R injury that functions by regulating inflammatory responses as well as apoptosis through TAK1‐dependent activation of the JNK/p38 pathways. Targeting hepatocytes, Steap3 may be a promising approach to protect the liver against I/R injury.
TCT-622 Respiration-Related Variations in Pd/Pa Ratio and Fractional Flow Reserve in Resting Conditions and During Intravenous Adenosine Administration
Authors: Rutger Feenstra, Gilbert Wijntjens, Valérie Stegehuis, Patrick Serruys, Amir Lerman, Javier Escaned, Marcel Beijk, Robbert de Winter, Jan Piek, Tim van de Hoef
Journal: Journal of the American College of Cardiology (2019)
TCT-249 Coronary Artery Perforations: Glasgow Natural History Study of Covered Stent Coronary Interventions (GNOCCI) study
Authors: Tom Ford, Andrew Morrow, Carly Adamson, John Paul Rocchiccioli, Aadil Shaukat, Mitchell Lindsay, Richard Good, Stuart Watkins, Hany Eteiba, Keith Robertson, Novalia Sidik, Damien Collison, Peter McCartney, Colin Berry, Keith Oldroyd, Margaret McEntegart
Journal: Journal of the American College of Cardiology (2019)
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
Authors: Jyh-Ming Liou, Chieh-Chang Chen, Chih-Min Chang, Yu-Jen Fang, Ming-Jong Bair, Po-Yueh Chen, Chi-Yang Chang, Yao-Chun Hsu, Mei-Jyh Chen, Chien-Chuan Chen, Ji-Yuh Lee, Tsung-Hua Yang, Jiing-Chyuan Luo, Chi-Yi Chen, Wen-Feng Hsu, Yen-Nien Chen, Jeng-Yih Wu, Jaw-Town Lin, Tzu-Pin Lu, Eric Y Chuang, Emad M El-Omar, Ming-Shiang Wu
Journal: The Lancet Infectious Diseases (2019)
A Teacher for All Seasons
Authors: Albert Khine
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-399 Long-Term Cardiovascular Outcomes According to the Antiplatelet Agent Discontinued After Coronary Stenting: Insights From 4 Xience V Post-Approval Studies
Authors: Davide Cao, Rishi Chandiramani, Ridhima Goel, Anastasios Roumeliotis, Moritz Blum, Vinuta Rau, Kai Koo, Samantha Sartori, Giulio Stefanini, Marco Valgimigli, Roxana Mehran
Journal: Journal of the American College of Cardiology (2019)
Epidemiology of Patients with Classical Philadelphia-Chromosome Negative Myeloproliferative Neoplasms at a Single Academic Medical Center in Singapore
Authors: Priscella Shirley Chia, Vanessa CL Chong, Ting Yuan Tay, Eng Soo Yap, Wee Joo Chng, Xin Liu, Moon Ley Tung
Journal: Blood (2018)
Two novel histone deacetylase inhibitors NVP-LAQ824 and NVP-LBH589 are active against biliary tract cancer and potentiate the efficacy of gemcitabine
Authors: M. Wiedmann, T. Bluethner, M. Niederhagen, K. Schoppmeyer, J. Moessner, K. Caca
Journal: Journal of Clinical Oncology (2006)

4149 Background: Chromatin remodelling agents such as histone deacetylase inhibitors have been shown to modulate gene expression in tumor cells and inhibit tumor growth and angiogenesis. NVP-LAQ824 and NVP-LBH589 are two novel chemical entities belonging to a cinnamic hydroxamic acid class of compounds. Little is known about their efficacy for the treatment of biliary tract cancer. Methods: Cell-growth inhibition by NVP-LAQ824 and NVP-LBH589 was studied in vitro in 7 human biliary tract cancer cell lines by MTT assay. In addition, the anti-tumoral effect of NVP-LBH589 was studied in a chimeric mouse model. Anti-tumoral drug mechanism was assessed by immunoblotting for p21 WAF-1 , acH3 Lys9 and acH4, cell cycle analysis, PARP assay, TUNEL assay, and immunhistochemistry for MIB-1. Results: In vitro treatment with both compounds significantly suppressed the growth of all cancer cell lines (mean IC 50 (3d) 0.08 and 0.04 μM, respectively) and was associated with hyperacetylation of nucleosomal histones H3 and H4, increased expression of p21 WAF-1 , cell cycle arrest at G2/M-checkpoint, and induction of apoptosis (PARP cleavage). After 28 d, NVP-LBH589 reduced tumor mass by 66% (bile duct cancer) and 87% (gallbladder cancer) in vivo in comparison to placebo and potentiated the efficacy of gemcitabine. Further analysis of the tumor specimens revealed increased apoptosis (TUNEL) and reduced cell proliferation (MIB-1). Conclusions: Our findings suggest that NVP-LBH589 &gt; NVP-LAQ824 are active against human biliary tract cancer in vitro. In addition, NVP-LBH589 demonstrated significant in vivo activity and potentiated the efficacy of gemcitabine. Therefore, further clinical evaluation of this new drug for the treatment of biliary tract cancer is recommended. No significant financial relationships to disclose.
Quantitative Results of a National Intervention to Prevent Central Line–Associated Bloodstream Infection
Authors: Payal K. Patel, M. Todd Greene, Karen Jones, Andrew J. Rolle, David Ratz, Ashley Snyder, Sanjay Saint, Vineet Chopra
Journal: Annals of Internal Medicine (2019)

Background: Central line–associated bloodstream infection (CLABSI) remains prevalent in hospitals in the United States. Objective: To evaluate the impact of a multimodal intervention in hospitals with elevated rates of health care–associated infection. Design: Pre–post observational evaluation of a prospective, national, clustered, nonrandomized initiative of 3 cohorts of hospitals. Setting: Acute care, long-term acute care, and critical access hospitals, including intensive care units and medical/surgical wards. Participants: Target hospitals had a cumulative attributable difference above the first tertile of performance for Clostridioides difficile infection and another health care–associated infection (such as CLABSI). Some hospitals that did not meet these criteria also participated. Intervention: A multimodal intervention consisting of recommendations and tools for prioritizing and implementing evidence-based infection prevention strategies, on-demand educational videos, webinars led by content experts, and access to content experts. Measurements: Rates of CLABSI and device utilization ratio pre- and postintervention. Results: Between November 2016 and May 2018, 387 hospitals in 23 states and the District of Columbia participated. Monthly preimplementation CLABSI rates ranged from 0 to 71.4 CLABSIs per 1000 catheter-days. Over the study period, the unadjusted CLABSI rate was low and decreased from 0.88 to 0.80 CLABSI per 1000 catheter-days. Between the pre- and postintervention periods, device utilization decreased from 24.05 to 22.07 central line–days per 100 patient-days. However, a decreasing trend in device utilization was also observed during the preintervention period. Limitations: The intervention period was brief. Participation in and adherence to recommended interventions were not fully assessed. Rates of CLABSI were low. Patient characteristics could not be assessed. Conclusion: In hospitals with a disproportionate burden of health care–associated infection, a multimodal intervention did not reduce rates of CLABSI. Primary Funding Source: Centers for Disease Control and Prevention.
Post-ERCP pancreatitis prophylaxis: is it really that complex?
Authors: Klaus Mönkemüller
Journal: Endoscopy (2019)

Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), occurring in about 3.5 % of unselected patients [1]. High risk patients should undergo pharmacological or mechanical measures to decrease post-ERCP pancreatitis (PEP), as PEP occurs in up to 25 % – 30 % of these patients [2]. Pharmacological approaches include rectal administration of indomethacin or diclofenac, sublingual administration of nitrates, and intravenous hydration [2]. The only mechanical approach recommended to prevent PEP is pancreatic duct (PD) stenting [2]. However, manipulation of the PD using wires and injection of contrast represent high risk interventions for the development of PEP [2]. Therefore, studies that investigate whether a pure pharmacological approach is equivalent to pharmacological intervention plus PD stenting in preventing PEP are of much interest. This is exactly what Sotoudehmanesh et al. from the Tehran University set out to investigate [3].
TCT-438 Prognosis of MitraClip Combined With Optimal Medical Therapy Versus Optimal Medical Therapy Alone in the Treatment of Functional Mitral Regurgitation: A Meta-Analysis of Randomized Controlled Trials and Propensity Score Matching Cohorts
Authors: Wasawat Vutthikraivit, Pablo Paz, Jakrin Kewcharoen, Pattara Rattanawong, Prapaipan Putthapiban, Veraprapas Kittipibul, Mohamed Elmassry, M. Rubayat Rahman, Saif El Nawaa, Barbara Mantilla, Scott Shurmur, Mohammad Mehdi Ansari
Journal: Journal of the American College of Cardiology (2019)
TCT-291 Comparison of Thromboresistance Between Everolimus-Eluting Fluoropolymer Stent and Currently Available Drug-Eluting Stent in an Ex Vivo Swine Shunt Model Under Only Single Antiplatelet Therapy
Authors: Hiroyuki Jinnouchi, Frank Kolodgie, Qi Cheng, Christine Janifer, Atsushi Sakamoto, Yu Sato, Anne Cornelissen, Laura Perkins, Renu Virmani, Aloke Finn
Journal: Journal of the American College of Cardiology (2019)
TCT-19 Outcome of Coronary Ostial Stenting to Prevent Coronary Obstruction During TAVR: An International Multicenter Registry
Authors: Antonio Mangieri, Francesco Gallo, Francesco Giannini, Alessandra Laricchia, Matteo Casenghi, Antonio Popolo Rubbio, Federico De Marco, Damiano Regazzoli, Bernhard Reimers, Gennaro Petriello, Alfonso Ielasi, Paola Purita, Chiara Fraccaro, Giuseppe Tarantini, Marco Ancona, Daniele Di Stefano, Matteo Montorfano, Nicolas Van Mieghem, Herbert Kroon, Stefan Toggweiler, Uri Landes, Azeem Latib, Francesco Bedogni, Antonio Colombo
Journal: Journal of the American College of Cardiology (2019)
TCT-164 Clinical Outcomes at 3 Years of the Absorb Bioresorbable Vascular Scaffold Versus Xience Drug-Eluting Metallic Stent in Patients With or Without Acute Coronary Syndrome: AIDA Trial Substudy
Authors: Ruben Tijssen, Laura Kerkmeijer, Sjoerd H. Hofma, Rene van der Schaaf, Auke Weevers, Robin Kraak, Jan Piek, Jan Tijssen, Robert de Winter, Jose P.S. Henriques, Joanna Wykrzykowska
Journal: Journal of the American College of Cardiology (2019)
TCT-813 Culprit-Vessel Versus Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: Insights From the National Cardiogenic Shock Initiative
Authors: Alejandro Lemor, Mir Basir, Kiritkumar Patel, Murad Salam, Theodore Schreiber, Amir Kaki, Tarun Jain, Ivan Hanson, Steven Almany, Steven Timmis, Simon Dixon, Brian Kolski, Josh Todd, Shaun Senter, Steven Marso, David Lasorda, Charles Wilkins, Thomas Lalonde, Antonious Attallah, Timothy Larkin, Allison Dupont, Jeffrey Marshall, Nainesh Patel, Michael Green, Behnam Tehrani, Alexander Truesdell, Rahul Sharma, Yasir Akhtar, Brian O’Neill, John Finley, Ayaz Rahman, Malcolm Foster, Raza Askari, Andrew Goldsweig, Scott Martin, Aditya Bharadwaj, Matheen Khuddus, Christopher Caputo, Denes Korpas, Ian Cawich, Navin Kapur, David McAllister, Nimrod Blank, M Chadi Alraies, Ruth Fisher, Akshay Khandelwal, Khaldoon Alaswad, Tyrell Johnson, Michael Hacala, William O’Neill
Journal: Journal of the American College of Cardiology (2019)
TCT-691 Clinical Results of Rescue Balloon Valvuloplasty for Severe Aortic Valve Stenosis in Patients With Severe Heart Failure and Cardiogenic Shock in a Community Hospital Without Onsite TAVR Facility
Authors: Antonios Kilias, Martin Steeg, Claudia Plachtzik, Wolfgang Bocksch
Journal: Journal of the American College of Cardiology (2019)
Updated Guidelines for Screening for Asymptomatic Bacteriuria
Authors: Lindsay E. Nicolle
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm
Authors: Aishwarya Ravindran, Rong He, Majd D. Jawad, Rhett P. Ketterling, Dong Chen, Jennifer L. Oliveira, Phuong L. Nguyen, David S. Viswanatha, Kaaren K. Reichard, James D. Hoyer, Ronald S. Go, Min Shi
Journal: Blood (2018)
Role of Adherence to Enhanced Recovery After Surgery Programs in Mitigating Health Care Disparities
Authors: Olga Rozental, Robert S. White, Roniel Weinberg
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
TCT-350 Intravascular Ultrasound, Optical Coherence Tomography, and Fractional Flow Reserve Use in Acute Myocardial Infarction: An 11-Year National Perspective
Authors: Saraschandra Vallabhajosyula, Stephanie El Hajj, Malcolm Bell, Abhiram Prasad, Amir Lerman, David Holmes, Gregory Barsness
Journal: Journal of the American College of Cardiology (2019)
TCT-838 Prognostic Value of High-Sensitivity C-Reactive Protein in Percutaneous Coronary Intervention According to Body Mass Index
Authors: Niklas Beyhoff, Davide Cao, Roxana Mehran, Moritz Blum, Samantha Sartori, Anastasios Roumeliotis, Ridhima Goel, Rishi Chandiramani, Asaad Khan, Prakash Krishnan, Nitin Barman, Usman Baber, George Dangas, Samin Sharma, Annapoorna Kini
Journal: Journal of the American College of Cardiology (2019)
Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates
Authors: Elias J. Dayoub, Joseph S. Ross, Nilay D. Shah, Sanket S. Dhruva
Journal: Circulation (2019)

C ◼ Medicare Part D ◼ venous thrombembolism In January 2019, the American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) guideline for atrial fibrillation (AF) was updated, recommending direct-acting oral anticoagulants (DOACs) over warfarin for patients with nonvalvular AF and no contraindication to DOACs. 1 The previous ACC/AHA/HRS guideline for AF and the most recent American College of Chest Physicians (CHEST) guideline for venous thromboembolism have also recommended an increased role for DOACs: the 2014 ACC/AHA/HRS AF guideline recommended either warfarin or DOACs as first-line antithrombotic therapy, 2 and in 2016, the CHEST venous thromboembolism guideline recommended DOACs over warfarin in noncancer patients. 3ormulary coverage and utilization management strategies can be used to promote guideline recommended medication use, but the impact of these guideline updates on DOAC formulary coverage is unknown.We characterized Medicare formulary changes after publication of the 2014 ACC/AHA/HRS and 2016 CHEST guidelines by using the Medicare Prescription Drug Plan Formulary Files, which include all available Medicare Advantage and stand-alone Part D plans, to compare coverage in the second quarters of 2013 (preguidelines), 2015 (post-ACC/AHA/HRS AF guideline), and 2017 (post-CHEST venous thromboembolism guideline) for DOACs (ie, apixaban, dabigatran, edoxaban, and rivaroxaban) at maintenance dosing for patients without impaired renal function, and for warfarin at a commonly prescribed dose (5 mg).We first determined formulary coverage and, among formularies providing coverage, determined formulary restrictiveness based on use of three utilization management strategies: cost-sharing tier-level 3 or higher, prior authorization requirement, and step therapy requirement.Formularies were categorized as unrestrictive if no approaches were used, restrictive if any approach was used, and no coverage.Chi-square or Fisher exact tests were used, as appropriate, to examine differences in formulary restrictiveness for each drug over the study period.Statistical tests were 2-sided, with P <0 .05indicating statistical significance.Institutional review board approval was not required for this study given that it was confined to analysis of data containing no patient information.For the second quarters of 2013, 2015, and 2017, there were 314, 389, and 378 Medicare Prescription Drug Plan formularies, respectively.All but 1 provided unrestrictive coverage of warfarin in all 3 time periods (Figure).Among DOACs, in 2013, 38 (12%) and 118 (38%) of formularies provided unrestrictive and restrictive coverage of apixaban, 64 (20%) and 245 (78%) of dabigatran, and 79 (25%) and 196 (62%) of rivaroxaban, whereas by 2017, 89 (24%) and 271 (70%) provided unrestrictive and restrictive coverage of apixaban, 92 (24%) and 276 (73%) of dabigatran, 115 (30%) and 261 (69%) of rivaroxaban, and 6 (2%) and 63 (17%) of edoxaban (P < 0.001).
Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia
Authors: Adrián Mosquera Orgueira, Beatriz Antelo Rodríguez, José Ángel Díaz Arias, José Luis Bello López
Journal: Blood Cancer Journal (2019)

The analysis of hundreds of chronic lymphocytic leukemia (CLL) exomes has shed new light on the heterogeneous genomic background characterizing this disease 1,2 .At the same time, the increased availability of exome-sequencing data comes along with a big bottleneck in the interpretation of its results, which is related to the remarkable heterogeneity in mutation detection between different bioinformatic protocols.Differences in clonality, purity, sequencing coverage, and quality constitue difficulties for most variant callers.The methods with the highest sensitivity are frequently accompanied by lower precision, leading to remarkable differences in mutation detection [3][4][5] .Therefore, we hypothesize that numerous variants in large sequencing projects have passed unnoticed.Here, we report the results of a complementary analysis performed on the International Cancer Genome Consortium (ICGC) CLL cohort 6 .The final analysis included 49 monoclonal B cell lymphocytosis and 390 treatmentnaive CLL samples.Mutation detection was performed with two different methods: VarsCan2, which uses a heuristic/statistical method for variant detection; and Platypus, which implements a Bayesian approach and local realignment of reads for indel and complex mutation detection.Variant quality was recalibrated using a logistic model, and drivers were detected by integrating the results of methods based on mutation frequency (MuSiC2), functional impact (OncodriveFM), co-
TCT-103 Wire Location by IVUS Strongly Predicts Procedural Success in the Retrograde Approach for Chronic Total Occlusions
Authors: Yongzhen Fan, Akiko Maehara, Myong Hwa Yamamoto, Juan Russo, Mitsuaki Matsumura, Fotios Gkargkoulas, Ziad Ali, Ajay Jayant Kirtane, Martin Leon, Gregg Stone, Jeffrey W. Moses, He Huang, Masahiko Ochiai, Dimitrios Karmpaliotis
Journal: Journal of the American College of Cardiology (2019)